Blog · Safety · Published 2026-08-09
Tirzepatide & Semaglutide Side Effects (2026): What's Common, What's Reported, and When to Call
For both tirzepatide and semaglutide, gastrointestinal effects dominate: nausea, constipation, diarrhea, vomiting, and reflux, concentrated during dose escalation and usually easing at stable doses. The labels add the serious-but-rarer tier — pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia when combined with insulin or sulfonylureas — plus the class boxed warning (thyroid C-cell tumors in rodents; contraindicated with personal/family MTC or MEN 2 history). Real-world reporting adds texture the trials didn't: fatigue, headaches, injection-site reactions, hair shedding with rapid loss, feeling cold, and 2026's most-searched curiosity — reduced interest in alcohol, now an active research area rather than just a Reddit theme.
Established vs reported: keeping the two lists honest
Trial-established effects carry rates; patient-reported patterns carry volume but no denominators — both matter, differently. Large-scale analyses of social posts confirm GI symptoms as the overwhelming real-world complaint, with temperature sensitivity and appetite-adjacent changes (including alcohol) appearing repeatedly. The alcohol signal is interesting enough that 2026 brought formal clinical research interest in GLP-1s and alcohol-use patterns — worth knowing, not worth self-prescribing for. One 2026 label note specific to high-dose semaglutide: Wegovy HD's 7.2 mg approval came with reports of altered skin sensation at the top dose. When symptoms are severe, persistent, or include severe abdominal pain, vision changes, or allergic signs — that's prescriber-now territory, and reportable to FDA MedWatch.
The compounded-specific layer most side-effect charts miss
Molecule effects are identical compounded or branded — but compounded use adds two mechanical risks the charts omit. Dosing errors: multi-dose vials plus concentration changes between fills drive the largest share of FDA's 730+ compounded-tirzepatide adverse-event reports; the vial-math routine is the defense. Product-quality variance: no premarket review means the pharmacy is the quality system — which is why "side effects" questions about compounded GLP-1s should start with the pharmacy-verification workflow. A symptom on a verified pharmacy's properly dosed product is medicine; the same symptom on an unverifiable vial is an open question. Cost pressure shouldn't decide this: verified programs span $145–$449, and verification is free.
Frequently asked questions
What are the most common tirzepatide side effects?
GI effects — nausea, constipation, diarrhea, vomiting, reflux — concentrated during dose increases. Fatigue, headaches, and injection-site reactions are commonly reported; serious-but-rare risks include pancreatitis and gallbladder disease, and the class boxed warning applies.
Are semaglutide side effects different from tirzepatide's?
Similar in kind — GI-dominant with the same warning tier. Head-to-head, adverse-event discontinuation ran modestly higher on tirzepatide; 2026's 7.2 mg semaglutide dose added label reports of altered skin sensation.
Does tirzepatide reduce alcohol cravings?
Many users report drinking less, and 2026 brought formal clinical research into GLP-1s and alcohol use. It's a real signal under study — not an approved use or a reason to self-adjust dosing.
Do compounded versions have extra side-effect risks?
The molecule is the same; the added risks are mechanical — vial dosing errors (the largest reported category) and pharmacy-dependent quality. Vial math and pharmacy verification address both.
Primary sources
FDA prescribing information for Zepbound and Wegovy (including 2026 label updates); FDA — unapproved GLP-1 concerns and adverse-event communications; published analyses of patient-reported GLP-1 experiences.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.